SCHEMBL16355239

SCHEMBL16355239

CCN(CC)c1ccc(NC(=O)c2cccc(C(=O)N(C)CCN3CCCN(C(=O)CCOCCOCCOCCOCCOCCOCCOCCOC)CC3)c2)c(-c2cc(C(=O)NC3CCCc4ccccc43)ccn2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 1/20 0.39
KMT2A Q03164 6/20 0.37
MEN1 O00255 4/20 0.37
ALDH1A1 P00352 6/20 0.36
KDM4E B2RXH2 5/20 0.36
HPGD P15428 4/20 0.36
CYP2D6 P10635 3/20 0.36
CYP1A2 P05177 2/20 0.36
PKM P14618 1/20 0.36
GAA P10253 1/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 2/20 0.35
TAS1R3 Q7RTX0 2/20 0.35
TAS1R1 Q7RTX1 2/20 0.35
TAS1R2 Q8TE23 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP2C9 P11712 1/20 0.35
HTR1A P08908 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6001227 1.00 SLC34A2 (0.39) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL18471352 0.95 SLC34A2 (0.38) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL18484293 0.95 SLC34A2 (0.38) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL10274777 0.94 SLC34A2 (0.38) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL15421032 0.94 SLC34A2 (0.37) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL15421034 0.94 SLC34A2 (0.37) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL46816 0.92 SLC34A2 (0.38) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL15420771 0.92 SLC34A2 (0.38) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL10274286 0.91 SLC34A2 (0.38) SLC34A2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL18040398 0.90 ALDH1A1 (0.35) SLC34A2KMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9301951-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2016-04-05 US disclosed
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2015-06-18 US disclosed
US-8916569-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2014-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A2, SLC34A1, SLC10A2 SLC34A2 1/4885KMT2A 4695/4885MEN1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.